Loading...
Market
Will the PrecivityAD2™ blood test be widely adopted in primary care settings by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Reports from major healthcare providers and industry publications
Story
New Blood Test Shows 90% Accuracy in Diagnosing Alzheimer's, JAMA Study Presented at AAIC 2024
Jul 28, 2024, 08:25 PM
A new blood test has shown promise in diagnosing Alzheimer's disease with 90% accuracy, outperforming traditional cognitive tests and CT scans. This development represents a significant step forward in the affordable and accessible diagnosis of Alzheimer's. The findings, presented at the Alzheimer’s Association International Conference (AAIC) 2024, suggest that blood tests could improve diagnosis in primary care, making testing less invasive and more accessible. The tests measure biomarkers such as phosphorylated tau and amyloid-beta, which are linked to Alzheimer's. Researchers reported that the blood test was significantly more accurate than doctors' interpretation of cognitive tests and CT scans. This advancement could lead to early diagnosis and timely access to new treatments, potentially accelerating research participation and treatment for millions. A JAMA study highlighted C2N Diagnostics’ PrecivityAD2™ blood test, which markedly improves accuracy of Alzheimer's diagnosis. The study involved about 1,200 patients in Sweden.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
0-5 • 25%
6-10 • 25%
11-15 • 25%
16 or more • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Yes • 50%
No • 50%
Widely adopted (>75% of clinics) • 25%
Moderately adopted (50-75% of clinics) • 25%
Sparsely adopted (25-50% of clinics) • 25%
Rarely adopted (<25% of clinics) • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%